Ken Griffin Verona Pharma PLC Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$15.46 - $30.16 $1.92 Million - $3.74 Million	-124,000 Reduced 88.51%	16,100 $463,000
Q2 2024 Aug 14, 2024	BUY	$11.48 - $17.02 $1.41 Million - $2.08 Million	122,400 Added 691.53%	140,100 $2.03 Million
Q1 2024 May 15, 2024	SELL	$15.3 - $20.24 $19,890 - $26,311	-1,300 Reduced 6.84%	17,700 $284,000
Q4 2023 Feb 14, 2024	BUY	$11.94 - $20.47 $132,534 - $227,217	11,100 Added 140.51%	19,000 $377,000
Q3 2023 Nov 14, 2023	SELL	$16.3 - $22.09 $184,190 - $249,617	-11,300 Reduced 58.85%	7,900 $128,000
Q2 2023 Aug 14, 2023	BUY	$19.41 - $23.43 $207,687 - $250,701	10,700 Added 125.88%	19,200 $405,000
Q1 2023 May 15, 2023	SELL	$18.06 - $25.27 $2.83 Million - $3.96 Million	-156,600 Reduced 94.85%	8,500 $170,000
Q4 2022 Feb 14, 2023	BUY	$9.84 - $26.13 $913,152 - $2.42 Million	92,800 Added 128.35%	165,100 $4.31 Million
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $108,053 - $354,699	26,100 Added 56.49%	72,300 $739,000

167

68.7M

704K

685K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.